Skip to Content

Protein Hints at a Fountain of Youth in Blood

It’s another tantalizing finding in an area of anti-aging research that has had mixed results.

A protein has been added to blood cells that appears to make them young again—cue the speculation on whether this substance is, at long last, a way to reliably reverse some of the effects of aging.

According to New Scientist, researchers discovered that older mice had low levels of a protein called osteopontin, and that stem cells injected into the mice quickly aged. The reverse—putting old stem cells into a dish filled with osteopontin—appeared to rejuvenate them. The team behind the work say they are developing a drug that they hope could be used to, as one of the researchers put it, “make old blood young again,” and boost older people’s immune systems.

The thing is, the gap between a bit of primary research and a clinically effective drug is huge—especially in the anti-aging arena. Several years ago, scientists and the public alike were excited to learn that when an old mouse and a young mouse were surgically joined so that they shared a circulatory system, the old mouse showed many signs of growing young again. The secret to prolonging life, it seemed, was in youthful blood.

Subsequent experiments have produced, you’ll forgive the expression, mixed results. In one, old blood turned out to be terrible for young mice, while young blood didn’t do much for the elderly. That hasn’t stopped the idea from getting the Silicon Valley treatment: Folks who pony up $8,000 to a startup called Ambrosia will receive a two-liter bagful of young-person blood plasma. The company’s founder is billing it as a clinical trial, but some say it looks a lot more like a scam.

What it comes down to is that no one knows what it is about young blood that causes the rejuvenation effect—or whether blood is even the most important part of the equation. Last year, a team of researchers at the Salk Institute genetically engineered mice so that they bore extra copies of genes known be able to turn back the biological clock on adult cells, transforming them into something resembling embryonic cells. By controlling the expression of these genes, the researchers were able to get the mice to live 30 percent longer than they normally would.

That doesn’t mean the discoverers of osteopontin are wrong to pursue their work. Clearly something very interesting is going on that suggests aging is not the immutable force we take it to be. The question that these and many other researchers are trying to answer, is just what that something is.

(Read more: New Scientist, The New York Times, “Questionable “Young Blood” Transfusions Offered in U.S. as Anti-Aging Remedy,” “Blood from Old Mice Makes Young Mice Decrepit”)

Keep Reading

Most Popular

Image of workers inspecting solar panels at a renewable energy plant
Image of workers inspecting solar panels at a renewable energy plant

Renewables are set to soar

The world will likely witness a wind and solar boom over the next five years, as costs decline and nations raise their climate ambitions.

light and shadow on floor
light and shadow on floor

How Facebook and Google fund global misinformation

The tech giants are paying millions of dollars to the operators of clickbait pages, bankrolling the deterioration of information ecosystems around the world.

wet market selling fish
wet market selling fish

This scientist now believes covid started in Wuhan’s wet market. Here’s why.

How a veteran virologist found fresh evidence to back up the theory that covid jumped from animals to humans in a notorious Chinese market—rather than emerged from a lab leak.

travelers walk through Ronald Reagan Washington National Airport
travelers walk through Ronald Reagan Washington National Airport

We won’t know how bad omicron is for another month

Gene sequencing gave an early alert about the latest covid variant. But we'll only know if omicron is a problem by watching it spread.

Stay connected

Illustration by Rose WongIllustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.